Alan Harvey

Prof

  • United Kingdom

1973 …2019

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal Statement

Alan Harvey is an emeritus professor of pharmacology in SIPBS. He studied pharmacy and then pharmacology, and has been an independent researcher since 1974. He works on the physiology and pharmacology of synaptic signalling, with particular interests in drugs and toxins affecting receptors and ion channels. He discovered the dendrotoxins, small proteins from mamba snake venoms that selectively block some types of potassium ion channels in neurons; these toxins have become standard pharmacological tools for investigating the role of particular ion channel sub-types in cellular physiology. In an extension to that work, he and collaborators in Sweden, Cuba, Argentina and Uruguay went on to discover other novel toxins with unusual chemical and pharmacological features: the fasciculins (the most potent and selective inhibitors of acetylcholinesterase), muscarinic toxins (the most sub-type specific compounds for studying muscarinic acetylcholine receptors), and the potassium ion channel blocking BgK and ShK; the last of these has formed the basis of an immunosuppressant drug that is in clinical trials. Recent toxin-related research was through involvement in a European consortium (“CONCO” - http://www.conco.eu/index.html) that explored the pharmaceutical potential of novel peptides from marine cone snails, particularly for treating patients with drug-resistant pain. He is President of the International Society on Toxinology (http://www.toxinology.org/) andwas Editor-in-Chief of the journal Toxicon (http://ees.elsevier.com/toxcon/) until 2017.

Together with colleagues in phytochemistry at Strathclyde, Alan Harvey has developed the use of natural products in drug discovery. This has been based on developing a facility for the rapid screening of chemicals on cell-based and molecular assays and on building up a world-wide network of natural product collaborators. The network involves groups in 20 different countries; it pioneered access and benefit-sharing arrangements for natural products that are compatible with the United Nations Convention on Biodiversity; and it created one of the most biodiverse screening collections available.

Alan Harvey has given many invited lectures at international conferences on toxins and venoms, natural products and drug discovery, and the academic-industrial interface. He has published extensively, with over 250 publications. On-going research activities include: 

  • discovery of new toxins that can be used as experimental tools to help understand the control of the excitability of nerve cells and the chemical signalling between nerves and muscles; and development of specific inhibitors of neuronal sodium ion channels as potential analgesics
  • linking with clinicians to study the underlying pharmacological effects responsible for currently unexplained symptoms of victims of envenoming by snakes
  • use of natural products in screening campaigns for potential leads for new medicines for cancer, inflammatory diseases, Alzheimer’s disease, and metabolic diseases and as antimicrobials and anti-parasitics
  • cell-based and molecular based drug discovery for prostate cancer
  • development of new assays for drug discovery projects
  • use of leads from traditional medicines in drug discovery projects for diabetes and trypanosomiasis

Keywords

  • drug discovery
  • Drug discovery from natural sources
  • venoms
  • toxins
  • synaptic transmission
  • Neuropharmacology
  • natural products

Fingerprint Dive into the research topics where Alan Harvey is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

  • Research Output

    Friends or foes? Emerging impacts of biological toxins

    Clark, G. C., Casewell, N. R., Elliott, C. T., Harvey, A. L., Jamieson, A. G., Strong, P. N. & Turner, A. D., 1 Apr 2019, In : Trends in Biochemical Sciences . 44, 4, p. 365-379 15 p.

    Research output: Contribution to journalArticle

    Open Access
    File
  • 9 Citations (Scopus)
    6 Downloads (Pure)

    Individual variability of venom from the European adder (Vipera berus berus) from one locality in Eastern Hungary

    Malina, T., Krecsák, L., Westerström, A., Szemán-Nagy, G., Gyémánt, G., M-Hamvas, M., Rowan, E. G., Harvey, A. L., Warrell, D. A., Pál, B., Rusznák, Z. & Vasas, G., 1 Sep 2017, In : Toxicon. 135, p. 59-70 12 p.

    Research output: Contribution to journalArticle

    Open Access
    File
  • 7 Citations (Scopus)
    45 Downloads (Pure)

    Thesis

    The effects of snake venoms as cytotoxins on selected prostate cancer cell lines

    Author: ABDALSAED, B. M., 10 Nov 2017

    Supervisor: Rowan, E. (Supervisor) & Harvey, A. (Supervisor)

    Student thesis: Doctoral Thesis

    Activities

    Improving the transition from toxins to medicines

    Alan Harvey (Speaker)
    24 Sep 2018

    Activity: Talk or presentation typesInvited talk

    19th Congress of the European Section of the International Society on Toxinology

    Alan Harvey (Participant)
    22 Sep 201826 Sep 2018

    Activity: Participating in or organising an event typesOrganiser of major conference

    Impacts

    MGB Biopharma licensed to treat deadly infections

    Colin Suckling (Participant), Iain Hunter (Participant), Alan Harvey (Participant), Simon MacKay (Participant), Curtis G. Gemmell (Participant)

    Impact: Impact - for External PortalEconomic and commerce, Health and welfare - new products, guidelines and services

    File